Urogen Pharma (URGN) Set to Release Quarterly Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) will likely be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Urogen Pharma to post earnings of $0.1057 per share and revenue of $89.92 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. On average, analysts expect Urogen Pharma to post ($0.20) EPS for the current fiscal year and $2.94 EPS for the next fiscal year.

Urogen Pharma Stock Performance

NASDAQ URGN opened at $32.72 on Monday. The company has a market capitalization of $1.60 billion, a P/E ratio of -16.53 and a beta of 1.57. Urogen Pharma has a one year low of $16.50 and a one year high of $50.81. The stock has a 50 day moving average price of $40.44 and a 200-day moving average price of $31.27.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on URGN. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Urogen Pharma in a report on Monday, October 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Wednesday. Guggenheim increased their price target on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $56.00 price objective on shares of Urogen Pharma in a report on Thursday, September 10th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $52.38.

Insiders Place Their Bets

In other news, CFO Chris Degnan sold 2,202 shares of the business’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the sale, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at approximately $167,343.09. The trade was a 32.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the transaction, the general counsel owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 65,269 shares of company stock valued at $3,037,646 in the last 90 days. 4.80% of the stock is owned by insiders.

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.